Navigation Links
Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
Date:6/30/2011

ams (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
2. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
5. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
6. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
7. Amylin Pharmaceuticals to Present Promising New Data on the Companys Diabetes Programs at ADA 2011
8. MKM Partners Hires Biotechnology/Specialty Pharmaceuticals Analyst
9. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three- and ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), Revenues for the third ... comparable period a year ago. The Company,reported a ...
... TNS Recovery Complex(R) and APS Corrective Complex(TM)-, ... Improvements in Skin Elasticity-, CARLSBAD, Calif., ... recent launch of TNS Essential Serum(TM) a ... two,cutting-edge treatments, TNS Recovery Complex(R) and APS ...
... New labeling reinforces strong safety profile of Ranexa ... a.m. ET/5:00 a.m. PT -, PALO ALTO, ... CVTX ) announced today that the U.S. Food ... line indication for,Ranexa(R) (ranolazine extended-release tablets) for the ...
Cached Biology Technology:EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5SkinMedica Launches TNS Essential Serum(TM) 2SkinMedica Launches TNS Essential Serum(TM) 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" report ... One major trend upcoming in this ... biomedical applications. Chemical sensors help in recording of patient ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 11, 2010) Van Andel Research Institute (VARI) ... cells that line and protect the prostate in relation to ... that normal cells and cancer cells depend on different factors ... cancer cells without affecting normal cells when developing treatments. ...
... In its collective efforts to develop new drugs, the ... on the application of natural biological transformation processes. One ... microorganisms or cells in a bioreactor filled with a ... especially strict regulations, the conditions inside the bioreactor need ...
... When conditions become complicated, there is no choice but ... Some of them growing in mining areas have unusual strengths, ... and knowing how to deal with this. Based on this ... as medicinal herbs for contaminated soils. The current level ...
Cached Biology News:VAI researchers develop tool to help study prostate cancer 2Clean sampling from bioreactors 2Plants in mining areas can cure soil affected by contamination in very short time 2Plants in mining areas can cure soil affected by contamination in very short time 3